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RNA–DNA hybrid model substrates which mimic an intermediate of Moloney murine leukemia virus (M-MuLV) reverse
transcription at the stage where the tRNAPro is removed were constructed. This substrate was used to assay the ability of
M-MuLV reverse transcriptase (RT) to cleave the RNA portion of the substrate. The cleavage specificities of the cognate
M-MuLV RT and the heterologous enzyme from the human immunodeficiency virus type-1 (HIV-1) were compared. M-MuLV
and HIV-1 RT recognize and cleave the RNA at distinct positions. The site of the initial RNase H cleavage in vitro was
determined using 3* end nearest neighbor analysis of the initial cleavage product. M-MuLV RT/RNase H removed the model
tRNAPro between the terminal ribo-A and ribo-C, resulting in a terminal ribo-A attached to the viral DNA, whereas HIV-1 RT/
RNase H was shown to cleave at the RNA–DNA junction. Analysis of the DNA over time indicated that the ribo-A is
subsequently removed by M-MuLV RT. In vivo analysis from double-LTR circle junctions illustrated that 16 of the 23 clones
isolated possessed the predicted junction if complete removal of the tRNA primer were to occur. The predicted junction
for complete removal of the tRNA primer was CATT-AATG. One aberrant circle junction was isolated which could result
from the use of an alternative primer. In contrast with HIV, no M-MuLV circle junctions were isolated which indicated
processing of a single-LTR terminus by integrase. Analysis from in vivo and in vitro studies indicate that the M-MuLV tRNAPro
primer is completely removed after plus-strand strong-stop synthesis. q 1997 Academic Press
INTRODUCTION scriptase has revealed several subdomains of the en-
zyme which include a finger, palm, thumb connection
Retroviruses contain RNA genomes which are repli-
and RNase H (Arnold et al., 1992; Jacobo-Molina and
cated through a DNA intermediate by the viral enzyme
Arnold, 1991; Jacobo-Molina et al., 1993; Kohlstaedt et
reverse transcriptase (RT) (Baltimore, 1970; Temin and
al., 1992). The N-terminal portion consists of the polymer-
Mizutani, 1970). Upon viral entry into a host cell, the
ization domain, and the C-terminal portion of the p66
subviral complex containing the genomic RNA molecules
subunit possesses the RNase H domain.
and limited viral proteins (Bowerman et al., 1989; Bukrin-
The minus-strand RNA primer for reverse transcription
sky et al., 1993; Farnet and Haseltine, 1991) is released
is a cellular tRNA. Factors which influence tRNA selec-
into the cytoplasm. The genomic RNA is then reverse
tion include binding to the RT (Barat et al., 1989; Haseltine
transcribed into double-stranded DNA by reverse tran-
et al., 1977; Panet et al., 1975; Sallafranque-Andreola et
scriptase, encoded by the viral pol gene. The linear dou-
al., 1989) and binding with the viral RNA primer-binding
ble-stranded DNA is randomly integrated into the host
site (PBS) (Kohlstaedt and Steitz, 1992; Leis et al., 1993).genome and expressed.
The tRNAs used to prime cDNA synthesis are character-Reverse transcriptase is a multifunctional enzyme pos-
istic of the particular retrovirus. Moloney murine leuke-sessing DNA-dependent and RNA-dependent polymer-
mia virus preferentially uses tRNAPro, HIV-1 utilizes tRNA-ase activities and RNase H activity. RNase H degrades Lys,3, and avian myeloblastosis virus RT utilizes tRNATrpRNA when present in an RNA–DNA hybrid. The polymer-
to prime cDNA synthesis. Studies by Wakefield et al.ase and RNase H activities of the Moloney murine leuke-
demonstrated that HIV-1 RT can utilize primers other thanmia virus (M-MuLV) reside in physically separable do-
tRNALys,3; however, in some instances a decreased kinet-mains of the monomeric protein p71 (Tanese et al., 1985).
ics of infection is observed (Wakefield et al., 1994). Simi-Human immunodeficiency virus type-1 (HIV-1) reverse
larly, isolates of M-MuLV have been found which aretranscriptase is a heterodimer which consists of two sub-
alternatively primed with tRNAGly (Colicelli and Goff, 1986)units, p51 and p66. The crystal structure of reverse tran-
although little preferential binding of a tRNA to the M-
MuLV RT has been identified (Levin, 1979; Panet and
1 Current address: Johns Hopkins University School of Medicine, De- Berliner, 1978).
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RNase H activity is required during reverse transcrip-Hunterian Bldg., Baltimore, Maryland 21205-2185.
tion to degrade the viral RNA template, for removal of2 To whom correspondence and reprint requests should be ad-
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the plus-strand polypurine tract (PPT) RNA primer. The although the fate of this terminal nucleotide in the replica-
tion pathway has not been identified (Schultz et al., 1995).position and site of removal of the two RNA primers used
in the reverse transcription reaction define the U3 and These results were in conflict with the limited number of
circle junctions previously analyzed (Colicelli and Goff,U5 boundaries. Incomplete removal of the tRNA during
reverse transcription could lead to altered cis-acting se- 1985; Shoemaker et al., 1980). In this study, a larger pool
of circle junctions were extensively analyzed indicatingquences normally required for integration. The RNase-
H-catalyzed removal of the tRNA primer after plus-strand that the terminal ribo-A of the tRNA is rapidly removed
after plus-strand strong-stop synthesis and before com-synthesis is important for second-strand synthesis to oc-
cur. Mutant viruses which lack RNase H activity have pletion of the full-length double-LTR linear product.
been shown to be noninfectious (Repaske et al., 1989;
Schatz et al., 1989; Tanese and Goff, 1988; Tisdale et al., MATERIALS AND METHODS
1991).
Enzymes
In vitro, RNase H activity has been classified as either
dependent or independent of polymerization events (Fur- Restriction enzymes, T4 RNA ligase, and T4 poly-
nucleotide kinase were purchased from New Englandfine and Reardon, 1991b). In the polymerase-dependent
mode, the RNase H active site lags approximately 18 Biolabs; recombinant RNasin was purchased from Pro-
mega. RNase T2 was purchased from GIBCO BRL. Exo-nucleotides behind the polymerase active site (Wohrl et
al., 1993, 1995a,b). Removal of the tRNA primer by RNase nuclease (0) Klenow polymerase was purchased from
United States Biochemical. M-MuLV reverse tran-H can be polymerase dependent (Furfine and Reardon,
1991a) or independent (Smith and Roth, 1992, 1993; Pul- scriptase was purified from Escherichia coli containing
the plasmid pB6B15.23 (Roth et al., 1985). M-MuLV RTlen et al., 1992). Active recombinant HIV-1 RNase H do-
mains have been isolated and characterized (Evans et al., was purified to near homogeneity and existed as a single
polypeptide by Coomassie staining. HIV-1 RT was puri-1991; Smith and Roth, 1993). The isolated HIV-1 RNase H
domain maintains specificity for removal of the tRNALys,3, fied to near homogeneity and contained two polypeptide
subunits of 66 and 51 kDa. HIV-1 reverse transcriptaseindicating the polymerase domain is not the sole determi-
nant for this recognition (Smith et al., 1994; Smith and was obtained from Jeffrey Culp, Department of Protein
Biochemistry, SmithKline Beecham Pharmaceuticals. M-Roth, 1992). Determinants for tRNA removal are intrinsic
to the RNase H domain. MuLV RT, purified from virions, was obtained from Alice
Telesnitsky. M-MuLV RT, with the authentic M-MuLV C-Many current studies focus on the use of alternate
tRNA primers with regard to initiation of reverse tran- terminus, was obtained from Millie Georgiadis. Sequenc-
ing reactions were performed by the dideoxynucleotidescription. Little research has been performed regarding
the efficient and complete removal of these primers after method (Sanger et al., 1977).
plus-strand strong-stop synthesis. Sequence alterations
Nucleotidesof the tRNA could result in altered alignment of the RNase
H domain on the tRNA and result in aberrant cleavages. Nucleotide triphosphates and nucleotide 3* mono-
This study focuses on analyzing the removal of the RNA phosphates were purchased from Sigma. [5*-32P]-
primer after plus-strand strong-stop synthesis is com- Cytidine-3*,5*-bis(phosphate) and [g-32P]ATP were pur-
pleted. A model substrate has been constructed which chased from ICN. [5*-a-32P]dATP was purchased from
is an RNA–DNA hybrid mimicking the U5/PBS border Amersham.
during M-MuLV reverse transcription. Analysis of the
HIV-1 RT on its cognate tRNA indicated the tRNALys,3 was Oligonucleotides
incompletely removed in vitro and in vivo (Smith et al.,
The RNA oligonucleotide MPR-1 (5* AUCCCGGAC-1990; Smith and Roth, 1992). In contrast, cleavage of the
GAGCCCCCA 3*) 18-mer and DNA 38-mer MTD-1 (5*M-MuLV RT on the HIV-1 substrate was less specific
GTCAGCGGGGGTCTTTCATTTGGGGGCTCGTCCGG-(Smith and Roth, 1992). The question of recognition of
GAT 3*) were purchased from Integrated DNA Technolo-reverse transcriptase on cognate and heterologous sub-
gies. All oligonucleotides were gel purified as previouslystrates is further extended in this study. The ability of the
described (Smith and Roth, 1992).RNase H domain of both HIV-RT and M-MuLV RT to
remove the tRNAPro encoded in the M-MuLV substrate
tRNA removal substrate preparation
was analyzed by an in vitro assay. The products of these
cleavage events were analyzed by 3* end analysis to To produce the substrate, 40 pmol of MPR-1 was 5*
end-labeled with [g-32P]ATP. Kinase reactions containeddetermine the initial site of cleavage. In vitro analysis of
the cleavage by M-MuLV RT/RNase H on its cognate 40 pmol MPR-1, RNasin (1.4 units/ml), T4 polynucleotide
kinase (0.7 units/ml), 320 mCi [g-32P]ATP (7000 Ci/mmol),tRNA substrate indicated that the tRNA is incompletely
removed. Similarly, cleavage at this position is reported 50 mM Tris–HCl, pH 7.6, 10 mM MgCl2 , and 10 mM
DTT. 5*-end-labeled MPR-1 was gel isolated and elutedto occur in endogenous reverse transcription reactions,
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overnight as described (Smith and Roth, 1992). The pel- 6 hr at 377. Products of the digestion were analyzed by
two-dimensional thin-layer chromatography on micro-lets were washed three times with 100% ethanol and
resuspended in diethyl pyrocarbonate-treated water. The crystalline cellulose plates (Kodak) containing a fluores-
cent indicator. The first dimension was performed inlabeled RNA was annealed to 40 pmol of MTD-1 in a 20-
ml reaction containing 50 mM Tris–HCl, pH 8.0, 50 mM isobutyric acid/saturated NH4OH/H2O (577/38/385) and
the second dimension was performed in saturatedKCl, 8 mM MgCl2 , and 2 mM DTT. The extension reac-
tions contained 0.4 mM dCTP, 0.4 mM dATP, 0.4 mM (NH4)2SO4/1 M sodium acetate/isopropyl alcohol (80/18/
2) as previously described (Konarska et al., 1985). 3*dGTP, 0.4 mM dTTP, 8 units Klenow Exo(0) polymerase
and were performed 5 min on ice, 5 min at room tempera- nucleotide monophosphate (NMP) and 3*,5* nucleotide
diphosphate standards were visualized by ultravioletture, and 1 hr at 377. The extension reactions were
stopped with addition of 22 ml formamide stop buffer, light. Radiolabeled NMP products were visualized by au-
toradiography.separated on a 15% denaturing polyacrylamide gel, gel
isolated, and resuspended in 20 ml RNase-free water.
Isolation and characterization of M-MuLV circleFor substrate in which the DNA portion was labeled,
junctions20 pmol MPR-1 was annealed to 20 pmol MTD-1 under
the same conditions as described above. The extension
Circle-junction intermediates of M-MuLV retroviral rep-
reactions were performed with the final reaction condi-
lication were isolated by infecting NIH/3T3 cells with
tions containing 0.4 mM dGTP, 0.4 mM dCTP, 0.4 mM
wild-type M-MuLV (2 ml); the DNA was isolated by the
dTTP, 0.2 mM dATP, 50 mM Tris–HCl, pH 8.0, 8 mM
Hirt method as previously described (Hirt, 1967). Circle-
MgCl2 , 2 mM DTT, and 8 units Exo(0) Klenow polymer- junction DNA intermediates were amplified by PCR using
ase, and 20 mCi [a-32P]dATP. The reactions were per-
primers 4091, CTCTTTTATTGAGCTCGGG [nucleotide
formed as described above.
8244–8226, M-MuLV (Shinnick et al., 1981)], and 5784,
AGTCCTCCGATTGACTGAG [nucleotide 6–24, M-MuLVRNase H cleavage assay
(Shinnick et al., 1981)]. PCR was performed using 0.25
mM each dNTP, 1.5 mM MgCl2 , 1.0 mM each primer, 20The annealed, extended RNA–DNA substrates were
incubated with HIV-1 or M-MuLV RT. Reactions (20 ml) mM Tris–HCl (pH 8.4), 50 mM KCl, 2.5 units Taq DNA
polymerase, and 10 ml (1/5 of a 100-mm plate) Hirt DNA.contained between 5 and 10 pmol of substrate (10 pmol
was used for pCp ligation experiments). Each reaction The cycling conditions were as follows: 2 min at 947,
followed by 29 cycles of 947 for 1 min, 537 for 1 min, andcontained 50 mM Tris–HCl, pH 7.5, 50 mM KCl, 2 mM
DTT, 8 mM MnCl2 or 8 mM MgCl2 , and either M-MuLV 727 for 3 min, and 1 cycle of 727 for 10 min. The PCR
reactions were separated on a 1.2% agarose gel. Thereverse transcriptase or HIV-1 reverse transcriptase, as
indicated. For experiments determining the initial site of expected 567-bp PCR product was gel isolated and puri-
fied by the glass powder method (Vogelstein and Gilles-cleavage, 0.22 pmol of M-MuLV RT was used and 0.11
pmol of HIV-1 RT was used. For analysis of the initial pie, 1979). The PCR product was digested with KpnI and
SacI, gel isolated, and ligated to KpnI/SacI-digestedcleavage product, 10 pmol of enzyme was used. The
reactions were all incubated at 377. Aliquots (3 ml) were pCOMB8 (Kang et al., 1991).
removed at 0 sec, 10 sec, 30 sec, 2 min, 5 min, 15 min,
Sequencing of MuLV circle junctionsand 30 min for reactions performed in MnCl2 . Aliquots
(3 ml) were removed at 0 sec, 30 sec, 2 min, and 5 min
The pCOMB8-positive clones containing an insert
for reactions performed in MgCl2 . Reactions were were sequenced by the dideoxynucleotide method using
stopped by the addition of formamide stop buffer. Reac-
AmpliTaq DNA polymerase (Perkin Elmer) (Sanger et al.,
tions were separated on 20% denaturing polyacryla-
1977). The plus-strand primer (6180) was 5* GGTCTC-
mide gel.
GCTGTTCCTTGGG 3* [nucleotides 79–97 of M-MuLV
(Shinnick et al., 1981)], and the minus-strand primer3* end analysis of isolated cleavage product
(6181) was 5* ATTTTTCCATGCCTTGCAA 3*, comple-
mentary to nucleotides 7886–7867 of M-MuLV (ShinnickThe initial RNase H cleavage product was isolated
from the 20% polyacrylamide gel and purified as de- et al., 1981). The primers were 5* labeled using [g-32P]-
ATP, 1 unit T4 polynucleotide kinase, and 50 mM Tris–scribed above. The isolated RNA products were then 3*
end labeled with 90 mCi of [5*-32P]pCp (2500 Ci/mmol) HCl, pH 7.6, 10 mM MgCl2 , and 10 mM DTT. The PCR
sequencing conditions were as follows: 1 cycle of 2 minand T4 RNA ligase under conditions previously described
(England and Uhlenbeck, 1978). The labeled RNA was at 957, followed by 30 cycles of 1 min at 957, 1 min at 687,
and 1 min at 727. Sequencing reactions were stopped byexcised from a 20% denaturing polyacrylamide gel. The
purified 3* and 5* dual-labeled product was then digested the addition of formamide stop buffer and were run on
a 10% polyacrylamide sequencing gel. The gel was driedwith RNase T2 in a 10-ml reaction containing 50 mM
ammonium acetate, pH 5.3, and 1.5 units of enzyme for and exposed to autoradiography film.
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FIG. 1. Analysis of RNA removal with M-MuLV tRNAPro model substrate. (A) The model RNA–DNA hybrid substrate which mimics the M-MuLV
replication intermediate for tRNAPro primer removal is shown. The substrate is a 38-mer in which the 5* RNA portion is (*) 32P radiolabeled. (B) Time
course analysis of RNase H cleavage with MnCl2 . Assays are performed as described under Materials and Methods. Lanes 1–7, HIV-1 RT,
representing 0-sec, 10-sec, 30-sec, 2-min, 5-min, 15-min, and 30-min time points, respectively. Lanes 8–14, M-MuLV RT representing 0-sec, 10-sec,
30-sec, 2-min, 5-min, 15-min, and 30-min time points, respectively. (C) Time course analysis of RNase H cleavage with MgCl2 . Assays were performed
as in B with MgCl2 as the divalent cation. Lanes 1–4, M-MuLV RT representing 0-sec, 30-sec, 2-min, and 5-min time points, respectively. Lanes 5–
8, HIV-1 RT representing 0-sec, 30-sec, 2-min, and 5-min time points, respectively. Lanes M indicate the 18-mer RNA marker. In B and C, (a)
indicates HIV-1 RT initial cleavage product and (b) indicates M-MuLV initial cleavage product.
RESULTS AND DISCUSSION substrate was incubated with Exo(0) Klenow polymerase
to produce the full-length 38-mer RNA–DNA hybrid. This
Assay for RNase H removal of tRNA
RNA–DNA hybrid mimics the intermediate found during
Figure 1A illustrates the model substrate that was uti- reverse transcription after plus-strand strong-stop syn-
lized to determine the specific site of cleavage by reverse thesis. This substrate was incubated with either M-MuLV
transcriptase-associated RNase H. The substrate mimics RT or HIV-1 RT and assayed for tRNA removal. In these
the U5/PBS border present in M-MuLV. An 18-mer RNA experiments, the RNA portion of the substrate was radio-
oligonucleotide was synthesized which was identical to labeled. Complete removal of the tRNA would result in
the 3* terminus of tRNAPro. This oligonucleotide was an- the production of an 18-mer RNA product; incomplete
nealed to a 38-mer DNA oligonucleotide and used as a removal would yield smaller products. A time course was
performed to determine the initial cleavage event by eachprimer to produce an RNA–DNA hybrid. The annealed
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enzyme (Fig. 1B). Since the 32P label is at the 5* terminus
of the RNA, the initial cleavage releases a 5*-32P-labeled
product at early time points. Subsequent cleavages will
release shorter 32P-labeled products which are also 5*-
labeled species or 5*-unlabeled products. Comparison
of the reaction products indicates that HIV-1 (Fig. 1B, left)
and M-MuLV RT (Fig. 1B, right) produce unique cleavage
patterns. In the time course shown, M-MuLV RT releases
a single distinct cleavage product (lanes 8–14, product
b), while HIV-1 RT (lanes 1–7) produced an initial cleav-
age product 1 base larger than M-MuLV (product a). Anal-
ysis of the earliest time point (10 sec) indicates that these
are in fact the initial cleavages. With time the RNA is
further degraded. Reactions performed with increased
concentrations of M-MuLV RT and HIV-1 RT did not alter
the cleavage patterns (data not shown).
Figure 1C shows the same reactions performed in the
presence of Mg2/ instead of Mn2/. The initial cleavage
products are the same for reactions performed in either
divalent cation, indicating that the result is not an artifact
of the divalent cation utilized. The initial cleavage product
for M-MuLV RT produced a cleavage product 1 base
smaller (product b) than that produced by HIV-1 RT (prod-
uct a).
If M-MuLV cleavage is occurring at the RNA–DNA
junction, it would suggest that HIV-1 RT is cleaving the
Moloney substrate within the DNA portion of the sub-
strate. In contrast, if HIV-1 RNase H is cleaving at the
RNA–DNA junction, then M-MuLV RNase H would be
incompletely removing the tRNA, an event which could
affect the LTR termini. The size of the products favor the
latter interpretation (data not shown).
3* end analysis of M-MuLV and HIV-1 cleavage
product
Due to the ambiguity in assigning the initial cleavage FIG. 2. Two-dimensional thin-layer chromatography analysis of the
site and the implications of the possible positions, it was initial cleavage products. Nearest neighbor analysis of the initial cleav-
age products. The initial RNA cleavage products produced by HIV-1necessary to further analyze the initial cleavage products
RT/RNase H (A) and M-MuLV RT/RNase H (B) were isolated, ligatedproduced by each enzyme. Large-scale RNase H cleavage
to [a-32P]pCp, incubated with RNase T2, and subjected to two-dimen-reactions were performed to permit 3* end analysis. The
sional thin-layer chromatography as described under Materials and
initial cleavage products were isolated and 3* labeled with Methods. The positions of the unlabeled 3* NMP are indicated by the
[5*-a-32P]pCp by incubation with T4 RNA ligase. The la- circles and are labeled Gp, Ap, Up, Cp. The migration of the marker
3*,5* pAp is indicated by the circle and the labeled product is a resultbeled products were subjected to digestion with RNase
of the initial 5* labeling of the RNA. Cleavage positions are indicatedT2, resulting in the transfer of the radiolabel to the 3*-
below; radiolabeled positions are indicated by an asterisk.terminal nucleotide. The digest was subjected to two-di-
mensional thin-layer chromatography in the presence of
the markers AMP, CMP, UMP, GMP, and pAp (Fig. 2). 3*. Based on the size of the released product and the 3*-
terminal nucleotide analysis, the results indicate that theFigure 2A shows that the 3* terminus of the RNA product
released by HIV-1 RT/RNase H comigrates with the UV HIV-1 RT is cleaving at the RNA–DNA junction. For M-
MuLV, size analysis indicated the cleavage product wasmarker 3* AMP. Figure 2b indicates that the 3* terminus
of the product released by the M-MuLV RT/RNase H comi- 1 nucleotide shorter than found with HIV (Fig. 1). This is
consistent with the 3* end analysis demonstrating a 3*-grates with the UV marker 3* CMP. The presence of the
labeled pAp product in both analyses is due to the initial terminal C residue for M-MuLV RT cleavage. The results
indicate that the initial RNase H cleavage of M-MuLV RT5* labeling of the RNA. The sequence of the RNA corre-
sponding to the tRNA is 5* AUCCCGGACGAGCCCCCA does not completely remove the tRNAPro.
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FIG. 3. Circle junction analysis of M-MuLV intermediates. (A) Scheme for amplification and isolation of the U5/U3 circle junction products. Positions
of the primers are indicated. PCR products were cloned into pCOMB8 using the restriction sites KpnI and SacI. (B) Sequence of the M-MuLV circle
junctions. The top line is the circle junction predicted for complete removal of the tRNAPro primer. The PBS and the PPT are underlined. Isolates
are grouped according to the presence of the predicted sequences, insertions, or deletions at the junction border. The inserted sequences are
indicated by the boxed areas. The number of isolates of each is indicated at the right. The arrow in B indicates the position where the alternative
primer may have been utilized to obtain the second insertion.
Incomplete removal of the tRNA has been found for sequence analysis of the U5/U3 border will determine
HIV-1 RT on its cognate tRNALys,3 both in vivo (Hong et whether the terminal ribo-A of the tRNAPro primer is in-
al., 1991; Jurriaans et al., 1992; Kulkosky et al., 1990; completely removed during reverse transcription in vivo.
Pauza, 1990; Smith et al., 1990) and in vitro (Furfine and The expected junction if the terminal ribo-A is removed
Reardon, 1991a; Smith and Roth, 1992; Pullen et al., would be 5* CATT-AAGT 3*. However, if the terminal ribo-
1992). Incomplete removal of the tRNA ultimately affects A remains, the expected junction would be 5* CATTT-
the termini of the viral LTRs. Analysis of the LTR termini AAGT 3*.
therefore reflects the RNase H process. The LTR termini Figure 3B shows the isolates that were observed.
can be analyzed in vivo directly or by analyzing the dou- Twenty-three isolates which possessed the U5/U3 junc-
ble-LTR circle junctions formed by the ligation and circu- tion were obtained. Sixteen of the 23 isolates possessed
larization of a full-length linear product. Incomplete re- the junction TT–AA. This would indicate that in the major-
moval of the tRNA has not been predicted for M-MuLV, ity of cases, the tRNA primer is completely removed dur-
based on the terminal analysis of viral LTRs (Roth et al., ing M-MuLV reverse transcription in vivo, in contrast to
1989), as well as limited analysis of circle junctions which that observed by HIV-1.
have been published (Colicelli and Goff, 1985; Shoe- Along with the 16 wild-type junctions, 2 clones pos-
maker et al., 1980). To verify this, a more extensive analy- sessed insertions while 5 possessed deletions. One in-
sis of circle junctions was performed. sertion contained two additional base pairs, TT-TA-AA.
Although the additional T may be the result of incomplete
Circle junction analysis of M-MuLV infected cells
removal of the tRNA, imprecise removal of neither the
tRNA or the PPT can explain the presence of the A. AM-MuLV was used to infect NIH 3T3 cells, and extra-
cellular enzyme with terminal transferase activity or achromosomal DNA was isolated by the Hirt method (Hirt,
reverse transcriptase may be responsible for adding nu-1967). Figure 3A represents the cloning scheme which
was used to PCR the double-LTR circle junction. DNA cleotides to the linear molecule (Patel and Preston, 1994).
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Schmidt–Ruppin A strains of Rous sarcoma virus have
been identified that possess additional nontemplate
base-pair additions (Olsen and Swanstrom, 1985). Circle
junctions with similar non-viral-encoded termini have
been isolated from HIV-infected cells (Hong et al., 1991;
Jurriaans et al., 1992; Kulkosky et al., 1990; Pauza, 1990;
Smith et al., 1990).
The second insertion found at the junction is quite
unusual. It consists of 38 nucleotides of M-MuLV, from
nucleotide 146 to 183. Although this sequence encodes
the PBS, it cannot be a result of incomplete removal of
the tRNA. Incomplete removal of the tRNA would result
in the additional sequences beyond the PBS being en-
coded by the tRNA. In contrast, in this isolate, the se-
quence is encoded by the viral genome, immediately
upstream of the PBS. One possible mechanism which
could yield this is the use of an alternative primer. The
use of an upstream primer would result in the sequence
through the PBS being encoded as DNA after minus-
strand synthesis. After completion of plus-strand synthe-
sis the PBS region would now be double-stranded DNA
rather than a double-stranded RNA–DNA hybrid and not
serve as a substrate for RNase H. If the plus-strand stop
product is released though, it would be functional for the
second-strand transfer reaction. The sequence immedi-
FIG. 4. Release of the DNA portion of the model substrate. (A) Theately adjacent to the insert contains the sequence 5*
18-mer RNA (MPR-1; indicated in bold) was annealed to the 38-merACCACCGACCACC 3* on the viral RNA, indicated by an
DNA oligonucleotide (MTD-1) and extended by Exo(0) Klenow DNAarrow in Fig. 3B, U5/PBS donor. If an alternative primer
polymerase in the presence of [a-32P]dATP. The positions of the incor-
was used, it would need to be complementary to this porated label are indicated by the asterisks. (B) Time course analysis
sequence. Computer search for an RNA which might of RNase H cleavage was performed by incubation of HIV-1 RT or M-
MuLV RT with the model RNA–DNA hybrid substrate. Lanes 1–6, HIV-serve as such a primer did not identify a candidate. An
1 RT incubated with MuLV substrate. Lanes 7–12, M-MuLV RT incu-alternative mechanism which would yield this insertion
bated with the MuLV substrate. Time points are indicated above eachwould be from an aberrant template switching event. It
lane. Positions of the input 38-mer substrate and the released 20-mer
is possible that an additional strand transfer occurs from and 21-mer DNA products are indicated at the right.
a completed (/) strand to an incomplete (0) strand, hy-
bridizing through the terminal inverted-repeat sequence
of the LTR. Partial synthesis through the PBS could result junctions support these observations and may reflect a
in these sequences present as a single-strand tail at the more stringent coordination of integration by M-MuLV IN
terminus of the full-length unintegrated provirus. Ligation over HIV IN.
and repair of this molecule would result in this type of
unusual circle junction identified in this study. Analysis of the fate of the terminal ribo-A
The five deletions obtained were either in the U5 or in
both U5 and U3 regions. The double-LTR circles result In vivo data indicated the 3*-terminal ribo A of the
tRNAPro was removed. In contrast, in vitro analysis of thefrom circularization of linear viral molecules, shunting
them out of the integration pathway. Clearly, substrates RNA cleavage indicated the ribo-A remained associated
with the DNA after the initial M-MuLV RNase H cleavage.which have lost the sequences required for integration
are expected to accumulate in this population. Quite in- It was necessary therefore to determine the fate of the
terminal ribo-A in vitro. A substrate was constructed interestingly, none of the junctions possessed LTR termini
characteristic of 3* processing catalyzed by the integrase which the DNA portion covalently linked to the RNA was
radiolabeled by incorporation of [a-32P]dATP during the(IN) protein. IN site-specifically cleaves the LTR termini
3* of the conserved CA, releasing a dinucleotide. Pro- extension reaction. Figure 4A represents the model sub-
strate in which the asterisk denotes the deoxynucleo-cessing of a single terminus was detected in circle junc-
tions of HIV (Kulkosky et al., 1990; Smith et al., 1990). tides which are radiolabeled. Analysis of the labeled RNA
(Fig. 1) indicated the initial cleavage occurs between theTight coordinated processing of the M-MuLV termini in
vivo has been reported (Murphy and Goff, 1989). The terminal ribo-A and ribo-C. This would result in a 21-
mer labeled DNA product. In this assay, no labeled RNAlack of single end 3* processing products in the circle
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products indicative of cleavage at the RNA–DNA junction
were found. This site would correspond to a 20-mer la-
beled DNA species. However, it was possible that the
ribo-A could be removed by an additional RNase H cleav-
age. In this analysis of the released RNA, this event
would not be observed since the RNA was 5*-terminally
end labeled. Analysis of the labeled DNA would indicate
the release of a 20-mer DNA product if it happened. A
time course was performed in order to determine if, over
time, a 20-mer resulted. Figure 4B represents the time
course reaction performed with 0.25 pmol of either M-
MuLV RT or HIV-1 RT. Lanes 1–6 represent substrate
incubated with HIV-1 RT. A 20-mer is the initial cleavage
product at 30 sec and is produced throughout the time
FIG. 5. Summary of MuLV RT and HIV-1 RT in vitro cleavage of MuLVcourse. This indicates that HIV-1 RT cleaves M-MuLV
model substrate. (A) HIV-1 RT upon incubation with M-MuLV model
substrate at the RNA–DNA junction, identical to that substrate initially cleaves at the RNA–DNA junction and completely
found in the RNA analysis (Fig. 1). Lanes 7–12 represent removes the tRNA primer. Secondary cleavages further digest the RNA.
(B) MuLV RT upon incubation with MuLV RT model substrate cleavessubstrate incubated with M-MuLV RT. Lane 8 illustrates
1 base away from the RNA–DNA junction within the tRNA primer. Thethat the predominant initial cleavage product is a 21-mer,
additional ribo-A, however, is rapidly removed due to an independentconsistent with the RNA analysis (Fig. 1). This confirms
nucleolytic event. This is consistent with the in vivo data which indicate
that the initial cleavage product is occurring between the that cleavage during reverse transcription completely removes the
terminal ribo-A and ribo-C. A lower level of 22-mer prod- tRNA primer. The vertical arrows indicate the sites of initial RNase H
cleavage, and the horizontal arrows indicate the sites of secondaryuct was also detected in the DNA analysis (lanes 8–12),
cleavages.which could result from cleavages corresponding with
the RNA products at the 02 position or by nontemplate
addition during the extension reactions. Interestingly, a tRNAPro at the RNA–DNA junction. The initial cleavage
occurs between the tRNAPro primer and the DNA border,time course analysis indicates that the DNA products
are shortened with time. Therefore, these data confirm which is subsequently further digested and released by
the RNase H. For M-MuLV RT, the cleavage pattern isthat the initial cleavage for M-MuLV RT in vitro occurs
within the tRNAPro but the terminal rA is subsequently more complex. M-MuLV RT initially cleaves in the RNA
portion between the terminal rA and rC. From there, aremoved. This is unlike the data that have been estab-
lished for HIV-1 RT/RNase H cleavage on an HIV-1 sub- secondary nucleolytic cleavage occurs removing the ter-
minal rA attached to the U5 DNA. Using this assay sys-strate in which the terminal rA remains bound with the
DNA after extensive incubation times (Smith, 1992). tem, it cannot be determined if this second cleavage is
the result of a 5* to 3* directional processing event or anTo rule out the possibility that the cleavage specificity
was a result of endogenous E. coli RNase H present in independent endonucleolytic cleavage. Digestion of the
remainder of the RNA proceeds, as found with HIV-1 RT,the recombinant extracts, virion-associated M-MuLV RT
was also used in the assay. The specificity of the initial in a 3* to 5* direction. In vivo, the circle junction analysis
yielded the predominate product with the sequence AA –cleavage product was the same as the bacterially ex-
pressed M-MuLV RTs used in these assays (data not TT, indicating complete removal of the tRNAPro. The in
vitro analysis indicated the terminal ribo-A is rapidly re-shown). A second M-MuLV RT preparation which con-
tained the authentic M-MuLV C-terminus was also moved, although it was not detected at the initial cleav-
age event. It is possible that in vivo, this rapid removaltested. This was assayed to eliminate the possibility that
the C-terminal 10 amino acids of RNase H were a deter- similarly occurs. However, analysis of the U5/U3 junc-
tions found in the double-LTR circle does not allow detec-minant for cleavage. Homology to the crystal structure
of E. coli RNase H did not predict these amino acids tion of these replication intermediates.
Recently, similar studies have been performed usingwould have an effect on the core RNase H structure
(Katayanagi et al., 1990; Yang et al., 1990). Experimen- alternative assays to address the question of tRNA re-
moval by the M-MuLV reverse transcriptase (Schultz ettally, no differences among the three M-MuLV RTs could
be detected (data not shown). al., 1995). Using primer extension assays, the initial
cleavage of M-MuLV was identified as occurring be-
tween the penultimate C and A of the tRNA. In contrast,Model of M-MuLV RT-associated RNase H cleavage
using a primer extension assay to analyze the fate of the
DNA, the rapid removal of the terminal ribo A was notFigure 5 summarizes the cleavages detected in vitro
on the M-MuLV substrate by M-MuLV RT and HIV-1 RT. detected at the efficiency presented in this article. It was
postulated that the sequence analyses of additional M-Figure 5A shows that HIV-1 RT removes the M-MuLV
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